Centre Hospitalier de Dunkerque
- Address
- lock Available on a paid plan
Centre Hospitalier de Dunkerque - Oncology and Pain Management Research
The Centre Hospitalier de Dunkerque is actively engaged in clinical research spanning hematologic malignancies and pain management. The center demonstrates expertise in both cutting-edge oncology trials and patient-centered pain relief interventions, contributing to evidence-based therapeutic advances across multiple medical disciplines.
- Relapsed/Refractory Multiple Myeloma and novel bispecific antibody therapies
- Comparative effectiveness studies in hematologic oncology treatment regimens
- Acute lumbosacral radiculopathy and neuropathic pain management
The center's oncology research includes participation in Phase 3 trials evaluating elranatamab monotherapy versus standard combination regimens in patients with relapsed/refractory multiple myeloma who have received prior anti-CD38 directed therapy. In parallel, their pain management research focuses on gabapentin efficacy for acute lumbosacral radiculalgia caused by disc herniation, utilizing rigorous double-blind, placebo-controlled methodology to establish evidence for analgesic interventions in musculoskeletal conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Pfizer Inc.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier de Dunkerque
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Gabapentin Versus Placebo for Acute Lumbosacral Radiculalgia Due to Disc Herniation: A Randomized, Double-Blind, Multicenter Study | Groupement Des Hopitaux De L'Institut Catholique De Lille | Phase III | Not Recruiting | Feb 2022 | Dec 2024 |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bortezomib | 1 | Unknown | 2024-05-27 | 2024-05-27 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.